GEMINA LABS LTD (8I7) - Net Assets

Latest as of October 2025: €-5.14 Million EUR ≈ $-6.01 Million USD

Based on the latest financial reports, GEMINA LABS LTD (8I7) has net assets worth €-5.14 Million EUR (≈ $-6.01 Million USD) as of October 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€1.11 Million ≈ $1.30 Million USD) and total liabilities (€6.25 Million ≈ $7.31 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 8I7 financial resilience to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	€-5.14 Million
% of Total Assets	-462.92%
Annual Growth Rate	N/A
5-Year Change	N/A
10-Year Change	N/A
Growth Volatility	N/A

GEMINA LABS LTD - Net Assets Trend (2022–2025)

This chart illustrates how GEMINA LABS LTD's net assets have evolved over time, based on quarterly financial data. Also explore 8I7 total asset value for the complete picture of this company's asset base.

Annual Net Assets for GEMINA LABS LTD (2022–2025)

The table below shows the annual net assets of GEMINA LABS LTD from 2022 to 2025. For live valuation and market cap data, see GEMINA LABS LTD stock valuation.

Year	Net Assets	Change
2025-01-31	€-4.44 Million ≈ $-5.19 Million	-179.78%
2024-01-31	€-1.59 Million ≈ $-1.85 Million	-2107.45%
2023-01-31	€-71.81K ≈ $-83.95K	-107.61%
2022-01-31	€944.23K ≈ $1.10 Million	--

Equity Component Analysis

This analysis shows how different components contribute to GEMINA LABS LTD's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 1526947400.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (January 2025)

Component	Amount	Percentage
Other Components	€16.40 Million	%
Total Equity	€-4.44 Million	100.00%

GEMINA LABS LTD Competitors by Market Cap

The table below lists competitors of GEMINA LABS LTD ranked by their market capitalization.

Company	Market Cap
CanadaBis Capital Inc V:CANB	$1.53 Million
Quartix Holdings Plc LSE:QTX	$1.53 Million
Ramsdens Holdings PLC LSE:RFX	$1.54 Million
Hexima Ltd AU:HXL	$1.54 Million
DELPHI WORLD MONEY LIMITED NSE:DELPHIFX	$1.53 Million
Ngenic AB ST:NGENIC	$1.53 Million
CBEYOND F:C5B	$1.52 Million
Aptitude Software Group PLC LSE:APTD	$1.52 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in GEMINA LABS LTD's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from -1,585,194 to -4,435,079, a change of -2,849,885.
Net loss of 4,073,658 reduced equity.
Other factors increased equity by 1,223,773.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	€-4.07 Million	-91.85%
Other Changes	€1.22 Million	+27.59%
Total Change	€-	%

Book Value vs Market Value Analysis

This analysis compares GEMINA LABS LTD's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2022-01-31	€0.02	€0.02	x
2023-01-31	€0.00	€0.02	x
2024-01-31	€-0.02	€0.02	x
2025-01-31	€-0.06	€0.02	x

Capital Efficiency Dashboard

This dashboard shows how efficiently GEMINA LABS LTD utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 0.00%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 0.00%
• Asset Turnover: 0.00x
• Equity Multiplier: 0.00x
Recent ROE (0.00%) is above the historical average (-125.37%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2022	-501.46%	0.00%	0.00x	1.50x	€-4.83 Million
2023	0.00%	0.00%	0.00x	0.00x	€-5.97 Million
2024	0.00%	0.00%	0.00x	0.00x	€-5.06 Million
2025	0.00%	0.00%	0.00x	0.00x	€-3.63 Million

Industry Comparison

This section compares GEMINA LABS LTD's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $698,488,333
Average return on equity (ROE) among peers: -63.13%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
GEMINA LABS LTD (8I7)	€-5.14 Million	-501.46%	N/A	$1.53 Million
TIZIANA LIFE SCIENCES LTD (0RP)	$5.54 Million	-319.56%	1.20x	$157.03 Million
Theravance Biopharma Inc (0TB)	$441.80 Million	197.40%	0.37x	$828.57 Million
PreveCeutical Medical Inc (18H)	$-4.10 Million	0.00%	0.00x	$3.34 Million
Argen-X (1AE)	$538.39 Million	-12.38%	0.07x	$44.01 Billion
WAVE LIFE SCIENCES LTD. (1U5)	$32.50 Million	-376.16%	5.37x	$1.12 Billion
ZAI LAB LTD0000006 (1ZLB)	$1.38 Billion	-51.05%	0.17x	$2.05 Billion
BioNTech SE (22UA)	$493.49 Million	-36.28%	0.62x	$23.24 Billion
Ascletis Pharma Inc (2VJ)	$2.54 Billion	-12.40%	0.05x	$2.05 Billion
ALPHAMAB ONCOLO.DL-000002 (3NK)	$1.56 Billion	-20.91%	0.36x	$978.26 Million
BIOMIND LABS INC. (3XI)	$-247.66K	0.00%	0.00x	$3.31 Million

About GEMINA LABS LTD

F:8I7 Germany Biotechnology

Market Cap

$1.61 Million

€1.38 Million EUR

Market Cap Rank

#29917 Global

#2626 in Germany

Share Price

€0.02

Change (1 day)

+0.00%

52-Week Range

€0.02 - €0.61

All Time High

€0.76